Mucopolysaccharidosis Type II (Hunters Disease (E76.1)
Hunter syndrome, clinically classified as Mucopolysaccharidosis type II (MPS II), is a progressive, inherited lysosomal storage disorder that causes structural tissue breakdown and multi-organ damage. Inherited as an X-linked recessive trait, the disease almost exclusively affects males. It is driven by mutations or structural deletions in the IDS gene, leaving the body deficient in the iduronate-2-sulfatase (I2S) enzyme. Without functional levels of this metabolic enzyme, complex sugar molecules called glycosaminoglycans (GAGs)—specifically dermatan sulfate and heparan sulfate—cannot be digested. Instead, they build up chronically within cellular lysosomes, expanding tissue mass and triggering a toxic cascade of cell death, skeletal deformity, and organic failure.
Causes
The etiology of Hunter Syndrome, also known as mucopolysaccharidosis type II (MPS II), involves inherited deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S) caused by mutations in the IDS gene located on the X chromosome. The disorder is inherited in an X-linked recessive pattern and therefore occurs predominantly in males, while females are typically carriers. Iduronate-2-sulfatase is responsible for degradation of the glycosaminoglycans (GAGs) dermatan sulfate and heparan sulfate within lysosomes. Mutations that impair or eliminate enzyme activity lead to progressive intracellular accumulation of these complex carbohydrates in multiple tissues and organs throughout the body. Over time, this lysosomal storage disrupts normal cellular function and triggers chronic inflammation, tissue remodeling, and organ dysfunction affecting the skeletal system, heart, airways, liver, nervous system, and connective tissues. Disease severity varies widely depending on the degree of residual enzyme activity, ranging from attenuated forms with slower progression to severe neuronopathic disease associated with profound neurocognitive decline.
Pathophysiology
The pathophysiology of Hunter Syndrome (mucopolysaccharidosis type II) results from deficiency of the lysosomal enzyme iduronate-2-sulfatase, leading to impaired degradation of the glycosaminoglycans dermatan sulfate and heparan sulfate. Because these complex carbohydrates cannot be adequately broken down, they progressively accumulate within lysosomes of cells throughout the body. The expanding lysosomal burden disrupts normal cellular metabolism, alters intracellular trafficking, impairs autophagy, and triggers chronic inflammatory and fibrotic signaling pathways. Over time, widespread glycosaminoglycan accumulation causes progressive dysfunction of connective tissue, cartilage, bone, heart valves, airways, liver, spleen, and vascular structures. In severe forms, deposition within the central nervous system contributes to neuroinflammation, neuronal dysfunction, hydrocephalus, and cognitive decline. The disease therefore represents a multisystem lysosomal storage disorder in which progressive substrate accumulation leads to cellular injury, tissue remodeling, organ enlargement, skeletal abnormalities, airway compromise, and progressive neurologic and cardiopulmonary deterioration.
Clinical features
The clinical features of Hunter Syndrome are progressive and multisystemic, typically emerging in early childhood as glycosaminoglycan accumulation worsens over time. Affected individuals commonly develop coarse facial features, macroglossia, short stature, hepatosplenomegaly, joint stiffness, skeletal deformities (dysostosis multiplex), and delayed growth. Airway narrowing, recurrent respiratory infections, obstructive sleep apnea, and hearing loss are frequent due to soft tissue thickening and abnormal connective tissue deposition. Cardiovascular involvement may include valvular heart disease, cardiomyopathy, and progressive vascular abnormalities. Many patients experience developmental delay, behavioral disturbances, and cognitive decline in the severe neuronopathic form of the disease, while attenuated forms may preserve intellectual function but still produce substantial somatic disease burden. Additional manifestations can include carpal tunnel syndrome, hydrocephalus, spinal cord compression, hernias, and reduced mobility. Because the disease progresses gradually, symptom severity and organ involvement vary considerably depending on residual enzyme activity and the specific IDS mutation present.
Diagnosis
The diagnosis of Hunter Syndrome is based on clinical suspicion supported by biochemical and genetic testing. Patients often present with progressive multisystem findings such as coarse facial features, hepatosplenomegaly, skeletal abnormalities, airway disease, joint stiffness, developmental delay, or cardiac involvement, prompting evaluation for a lysosomal storage disorder. Initial laboratory testing commonly demonstrates elevated urinary glycosaminoglycans, particularly dermatan sulfate and heparan sulfate. Definitive diagnosis is established by demonstrating reduced or absent iduronate-2-sulfatase enzyme activity in leukocytes, fibroblasts, or blood samples, followed by molecular genetic testing confirming pathogenic mutations in the IDS gene. Imaging studies may reveal dysostosis multiplex, hydrocephalus, spinal abnormalities, or organ enlargement, while echocardiography and pulmonary evaluation help assess systemic involvement. Early diagnosis is especially important because enzyme replacement therapy and emerging gene-based treatments may slow disease progression and improve long-term outcomes.
Mechanism of action videos
Therapeutic area: Metabolic